The plasminogen activator system in fibroblasts from systemic sclerosis

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 891-900

  Postiglione, Loredana ^a   Montuori, N ^a   Riccio, A ^a   Di Spigna, G ^a   Salzano, S ^a   Rossi, G ^a   Ragno, P ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Fibroblasts; Systemic sclerosis; Urokinase Plasminogen Activator (uPA); Urokinase Plasminogen Activator Receptor (uPAR)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ADULT; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS;

EID: 78149269955     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300325     Document Type: Article

References (30)

1. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998; 17:48-4.
2. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004; 16:739-45.
3. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007; 56:334-44.
4. Irigoyen JP, Muñoz-Cánoves P, Montera L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56:104-32.
5. Hannocks MJ, Oliver L, Gabrilove JL, Wilson EL. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood 1992; 79:1178-84.
6. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol 1986; 136:2883-891.
7. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266:1926-33.
8. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-43.
9. Gårdsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007; 282:13561-72.
10. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006; 63:1028-37.
11. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005; 93:192-98.
12. Caiolfa VR, Zamai M, Malengo G, et al. Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies. J Cell Biol 2007; 179:1067-82.
13. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86:4007-24.
14. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243:21-6.
15. D'Alessio S, Fibbi G, Cinelli M, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50:3275-85.
16. Serrati S, Cinelli M, Margheri F, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol 2006; 210:240-8.
17. Margheri F, Manetti M, Serrati S, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006; 54:3926-38.
18. Bandinelli F, Bartoli F, Perfetto E, et al. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). Clin Exp Rheumatol 2005; 23(5):671-77. Erratum in: Clin Exp Rheumatol 2005; 23:917.
19. Shimizu Y, Mizutani H, Inachi S, Tsuchibashi T, Shimizu M. Related Articles, Links Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis. J Dermatol 1994; 21:755-9.
20. Ciompi ML, Bazzichi L, Melchiorre D, De Giorgio F, Bondi F, Puccetti L. A placebo-controlled study on urokinase therapy in systemic sclerosis. Biomed Pharmacother 1996; 50:363-8.
21. Hart DA, Whidden P, Green F, Henkin J, Woods DE. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 1994; 17:69-76.
22. Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. Biol Chem 1992; 267:18224-9.
23. Matsushita M, Yamamoto T, Nishioka K. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 2005; 139:429-38.
24. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003; 163:445-52.
25. Tuan TL, Wu H, Huang EY, Chong SS, Laug W, Messadi D, Kelly P, Le A. Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures. Am J Pathol 2003; 162:1579-89.
26. Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE. Serum TIMP-1, TIMP-2 and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon and in normal controls. Ann Rheum Dis 2001; 60:846-51.
27. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108:281-4.
28. Zhang G, Kim H, Cai X, López-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003; 14:1254-71.
29. Kessler-Becker D, Smola S, Krieg T, Eckes B. High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro. Exp Dermatol 2004; 13:708-14.
30. Postiglione L, Ladogana P, Montagnani S, et al. Effect of Granulocyte Macrophage-Colony Stimulating Factor on extra-cellular matrix deposition by dermal fibroblasts from patients with Scleroderma. J Rheumatol 2005; 32:656-64.